Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis
Clinch, T.E.; Hobden, J.A.; Hill, J.M.; O'Callaghan, R.J.; Engel, L.S.; Kaufmann, H.E.
Clao Journal Official Publication of the Contact Lens Association of Ophthalmologists Inc 18(4): 245-247
1992
ISSN/ISBN: 0733-8902 PMID: 1424060 Document Number: 397230
We compared collagen shields hydrated in 1.36% tobramycin with topical 1.36% tobramycin for sustained treatment of experimental Pseudomonas keratitis in rabbits. Antibiotic therapy for a total of 24 hours was initiated 14 hours after an intrastromal injection of 10-3 logarithmic phase Pseudomonas aeruginosa. Seven groups were treated as follows: groups 1-3, collagen shields hydrated in tobramycin supplemented with topical 1.36% tobramycin drops at 4, 6, or 8 hour intervals; group 4, collagen shields hydrated in tobramycin without any further topical supplementation; group 5, topical tobramycin therapy, initially every half-hour for 4 hours, then hourly; group 6, collagen shields hydrated in balanced saline solution; and group 7, no treatment. Each group contained four eyes. The groups treated with collagen shields supplemented every 4 or 6 hours with topical tobramycin had significantly fewer colony forming units (CFU) than those receiving topical or collagen shield therapy alone (P lt 0.001). The group treated with collagen shields hydrated in sterile saline had 10-7 CFU per cornea, which was not significantly different from the untreated group (P gt 0.2). Collagen shields hydrated in tobramycin and supplemented with topical tobramycin were effective in sustained treatment of experimental Pseudomonas keratitis.